Publications

1. Avelumab (Bavencio®) in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma

   The National Health Care Institute has completed its assessment whether avelumab (Bavencio®) in combination with axitinib can be ...

   Report | 21-09-2020

2. GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis

   The National Health Care Institute completed its assessment whether an extension is possible of the conditions of List 2 of the ...

   Report | 17-08-2020

3. Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease

   The National Health Care Institute has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult ...

   Report | 03-07-2020

4. Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)

   The National Health Care Institute has completed its assessment whether ibrutinib (Imbruvica®) for the treatment of adult ...

   Report | 03-07-2020

5. GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over

   The National Health Care Institute has completed its assessment whether trifarotene (50 microgram/gram cream) (Aklief®) for the ...

   Report | 11-06-2020

6. Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)

   Zorginstituut Nederland has completed its reassessment of the pharmaco-economic analysis of dabrafenib in combination with ...

   Report | 02-06-2020

7. International strategic agenda 2020 National Health Care Institute

   The international strategic agenda 2020 describes the international activities of the National Health Care Institute ...

   Publication | 31-05-2020

8. Oral semaglutide (Rybelsus®) for the treatment of adults with insufficiently controlled type 2 diabetes mellitus

   The National Health Care Institute has completed its assessment whether oral semaglutide (Rybelsus®) is interchangeable with a ...

   Report | 29-05-2020

9. Specialist medicinal products assessment procedure

   Zorginstituut Nederland only assesses specialist medicinal products that pose a risk to the accessibility, affordability or ...

   Report | 11-05-2020

10. Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions

    The National Health Care Institute has completed its assessment whether pentosan polysulfate sodium (Elmiron®) is interchangeable ...

    Report | 28-04-2020